. 2020 Jun 3;66(5):1556–1564. doi: 10.1007/s10620-020-06368-2

Table 1.

Clinical characteristics of study patients

Clinical data	Responders		Non-responders		P value
Clinical data	Number	%	Number	%	P value
Patients	15	75	5	25
Age	43 (20–79)^a		34 (18–66)^a		NS
Male	9	60	5	100	NS
Allergy
Inhalant allergy	11	73	2	40	NS
Hay fever	7	47	1	20	NS
Food allergy	4	27	2	40	NS
No allergy	3	20	2	40	NS
Food and inhalant allergy	3	20	1	20	NS
Eczema	0	0	1	20	NS
Eosinophilic esophagitis
Previous bolus obstruction^b	8	53	4	80	NS
Previous esophageal dilation	2	13	0	0	NS
Current symptoms
Dysphagia	15	100	5	100	NS
Chest pain	13	87	1	20	0.014
Food impaction	10	67	4	80	NS
Cough	8	53	1	20	NS
Nausea/vomiting	6	40	3	60	NS
Current esophageal findings
Linear furrows	10	67	3	60	NS
Plaques	7	47	4	80	NS
Trachealization	11	73	4	80	NS
Strictures	8	53	1	20	NS
Peak eosinophil counts/HPF before treatment	30 (15–80)^a		25 (17–70)^a		NS
Peak eosinophil counts/HPF after treatment	0 (0–13)^a		30 (20–38)^a		< 0.001
Histologic response to treatment
< 15 peak eosinophil counts/HPF	15	75	0	0	< 0.001
> 50% reduction of peak eosinophil counts/HPF	14	70	0	0	< 0.001
> 75% reduction of peak eosinophil counts/HPF	13	65	0	0	0.0014
Blood eosinophil counts^c					NS
before treatment	0.36 (0.054–1.08)^a,d		0.46 (0.25–1.97)^a,e
after treatment	0.20 (0.077–0.47)^a,d		0.36 (0.29–0.60)^a,e		0.0037
Watson dysphagia scale summary score
before treatment	18 (4–31)^a		17 (0–23)^a		NS
after treatment	12 (0–27)^a		21 (0–24)^a		NS

HPF high-power field = 0.229 mm²; NS Nonsignificant

^aMedian (min–max)

^bRequiring hospital care for removal of bolus

^cEosinophil number × 10⁹ cells/L blood, ref 0.04–0.4 × 10⁹/L

^dP = 0.015 when comparing responders before and after treatment. Wilcoxon matched-pairs test

^eP = NS when comparing non-responders before and after treatment. Wilcoxon matched-pairs test